A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This multi-center, non-drug study will explore the relationship between exploratory biomarkers and functional dimensions in male adult individuals with Autistic Disorder or Asperger's Syndrome and healthy volunteer controls. Subjects will undergo a number of assessments on study visit Day 1.
| Condition |
|---|
|
Asperger's Syndrome, Healthy Volunteer, Autistic Disorder |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A Multi-center, Non-drug Study to Explore the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome. |
- Behavior assessment ratings [ Time Frame: approximately 5 months ] [ Designated as safety issue: No ]
- Cognition assessment ratings [ Time Frame: approximately 5 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | September 2013 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Cohort |
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
High functioning (IQ >70) male adult individuals with Autistic Disorder or Asperger's Syndrome and age and IQ matched healthy male volunteers
Inclusion Criteria:
Individuals with Autistic Disorder or Asperger's Syndrome:
- Male adults, 18 to 45 years of age inclusive
- Diagnosis of Autistic Disorder or Asperger's Syndrome as defined by DSM-IV
- IQ >70
- Body mass index (BMI) 18 to 35 kg/m2
- Availability of a reliable caregiver, able and willing to provide information regarding the individual's behavior and symptoms
Healthy controls:
- Healthy male adults, 18 to 45 years of age inclusive
- IQ >70
- Body mass index (BMI) 18 to 30 kg/m2
Exclusion Criteria:
General exclusion criteria:
- Positive test for drugs of abuse or alcohol
- Confirmed systolic blood pressure >140 or <90 mmHg, and diastolic blood pressure >90 or <50 mmHg
- Resting pulse rate >100 or <40 beats per minute
- Alcohol and/or substance abuse/dependence during the last 12 months
- Concomitant disease or condition that could interfere with, or treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
Additionally for individuals with Autistic Disorder or Asperger's Syndrome:
History of epilepsy/seizure disorder (except simple febrile seizures)
- Significant disruptive, aggressive or self-injurious, or sexually inappropriate behavior during the last 3 months that in the opinion of the investigator might interfere with the conduct of the study
Additionally for healthy controls:
- Clinically significant abnormalities in laboratory test results
- History of or current psychiatric, neurological disorder or pervasive developmental disorder
Contacts and Locations| Contact: Reference Study ID Number: BP28421 www.roche.com/about_roche/roche_worldwide.htm | 888-662-6728 (U.S. Only) | global.rochegenentechtrials@roche.com |
| United States, California | |
| Recruiting | |
| Los Ageles, California, United States, CA 90095 | |
| United States, New York | |
| Recruiting | |
| New York, New York, United States, 10021 | |
| Study Director: | Clinical Trials | Hoffmann-La Roche |
More Information
No publications provided
| Responsible Party: | Hoffmann-La Roche |
| ClinicalTrials.gov Identifier: | NCT01669889 History of Changes |
| Other Study ID Numbers: | BP28421 |
| Study First Received: | August 15, 2012 |
| Last Updated: | June 3, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Autistic Disorder Asperger Syndrome Child Development Disorders, Pervasive Mental Disorders Diagnosed in Childhood Mental Disorders |
ClinicalTrials.gov processed this record on June 18, 2013